Trijardy XR FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 28, 2021.
FDA Approved: Yes (First approved January 27, 2020)
Brand name: Trijardy XR
Generic name: empagliflozin, linagliptin and metformin hydrochloride
Dosage form: Extended-Release Tablets
Company: Boehringer Ingelheim and Eli Lilly and Company
Treatment for: Diabetes, Type 2
Trijardy XR (empagliflozin/linagliptin/metformin hydrochloride) is a fixed-dose combination of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance), the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin (Tradjenta) and the biguanide metformin hydrochloride indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Development timeline for Trijardy XR
| Date | Article |
|---|---|
| Jan 27, 2020 | Approval FDA Approves Trijardy XR (empagliflozin/linagliptin/metformin) for Type 2 Diabetes in Adults |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
